Lipoic acid outperforms Ocrevus (Ocrelizumab)
Posted: Thu Sep 21, 2017 8:24 pm
Source: https://www.medicalnewstoday.com/articl ... 5.php?iacp
Lipoic acid outperformed ocrelizumab
Whole brain atrophy refers to the reduction in total brain volume due to the loss of neurons, and it is considered a marker of MS progression.
For their randomized, double-blind study, Dr. Spain and team enrolled 51 adults aged between 40 and 70 years, all of whom had been diagnosed with SPMS.
A total of 27 participants were randomized to receive 1,200 milligrams of lipoic acid every day for 2 years, while the remaining 24 subjects received a placebo.
The brain volume of each participant was assessed at study baseline using MRI. MRI scans were also conducted each year thereafter, in order to pinpoint any changes in subjects' brain volume.
Compared with participants who took the placebo, the researchers found that those who took lipoic acid showed a 68 percent reduction in the rate of whole brain atrophy.
For comparative purposes, the team notes that the drug ocrelizumab (brand name Ocrevus) - which was recently approved by the Food and Drug Administration (FDA) for the treatment of primary progressive MS - improved whole brain atrophy by 18 percent in clinical trials.
Lipoic acid outperformed ocrelizumab
Whole brain atrophy refers to the reduction in total brain volume due to the loss of neurons, and it is considered a marker of MS progression.
For their randomized, double-blind study, Dr. Spain and team enrolled 51 adults aged between 40 and 70 years, all of whom had been diagnosed with SPMS.
A total of 27 participants were randomized to receive 1,200 milligrams of lipoic acid every day for 2 years, while the remaining 24 subjects received a placebo.
The brain volume of each participant was assessed at study baseline using MRI. MRI scans were also conducted each year thereafter, in order to pinpoint any changes in subjects' brain volume.
Compared with participants who took the placebo, the researchers found that those who took lipoic acid showed a 68 percent reduction in the rate of whole brain atrophy.
For comparative purposes, the team notes that the drug ocrelizumab (brand name Ocrevus) - which was recently approved by the Food and Drug Administration (FDA) for the treatment of primary progressive MS - improved whole brain atrophy by 18 percent in clinical trials.
